A Brand New Network for Gene
A global network of drug developers united in accelerating the delivery of safe,
efficacious and accessible gene therapies to rare disease patients
A private network for gene therapy drug developers
designed by gene therapy drug developers
2022 was a landmark year for the global gene therapy space. Last August came the green light for bluebird bio’s Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels, we saw the accelerated approval of another bluebird bio product, Skysona.
As the gene therapy field continues to break records, there are still significant challenges to overcome relating to safety, efficacy, and accessibility.
For this reason, your peers from some of the most innovative pharma and biotech companies have designed the Gene Therapy for Rare Disorders Searchlight network to accelerate the safe delivery of gene therapies to rare disorder patients.
Its purpose is to assemble unique experience-sharing collectives of gene therapy specialists to work together to tackle their most pressing shared clinical, manufacturing and regulatory challenges
It is the only global gene therapy network focused on rare disorders that allows the whole team to engage in the timely, targeted exchanges of experiences and ideas in mission-critical pre-competitive areas.
Join your peers today and be part of a global community of like-minded individuals:
Business critical conversations
Virtual cornerstone meetings
We facilitate, structured, discussion-driven, Gene Therapy-focused quarterly meetings for member companies.
Each high-impact 90-minute meeting takes place virtually via Zoom. The meeting agenda is carefully curated and focused on the topics and critical challenges requested by Searchlight members.
Member companies are represented by one internal champion with strategic oversight over its Gene Therapy program to ensure that each discussion is high-value, high-impact, and delivers tangible outputs for members to take back to their organization.
Innovation doesn't happen in isolation
Searchlight makes meaningful progress
“Many of the working groups that are already out there are so similar, but this is different because it’s so focused, structured and value-driven, which makes it a need-to-attend, not a nice-to attend, which is why we are taking part.”
“We’ve all got internal expertise, but we need more external perspective. There’s so much value to be gained from a facilitated, structured network like this because it focuses sharing the lessons learned from failures as well as successes.”
“There’s more accepted practice that isn’t documented in GTx than anywhere else. If you need specific information about the art, you need to know someone who has the answer. This network will help us find the answers we need faster.”
The Searchlight platform
Network with the best in the field
Gain insider knowledge and insights from scientific advisors
Senior Research Associate
National Institute of Biology
For more information on what’s included as part of the Gene Therapy for Rare Disorders: Searchlight membership, please download the membership brochure.
Here’s what you’ll learn more about:
- The unique mission and purpose of the network
- What membership includes
- How the quarterly cornerstone meetings work
- How bespoke value delivery works
- How we deliver demonstrable value to you
- Annual member investment
The Searchlight platform
Build meaningful relationships and gain value all year around
Contact fellow members via the private or group chat features.
Come together with leaders throughout the community at virtual cornerstone meetings and in-person gatherings at Hanson Wade conferences.
Explore the library of business critical content and videos on demand via the thematic rooms and content channels.